Moreover, our analysis revealed that high expression of <i>TMTC1</i> was associated with worse overall survival (OS) outcomes in patients with ACC, BLCA, COAD, GBM, KIRP, OV, STAD, and UCEC, but better OS outcomes in patients with CESC, KIRC, LUSC, and PAAD. Here, TMTC1 is linked to bladder transitional cell carcinoma.